JP2024520205A5 - - Google Patents
Info
- Publication number
- JP2024520205A5 JP2024520205A5 JP2023571857A JP2023571857A JP2024520205A5 JP 2024520205 A5 JP2024520205 A5 JP 2024520205A5 JP 2023571857 A JP2023571857 A JP 2023571857A JP 2023571857 A JP2023571857 A JP 2023571857A JP 2024520205 A5 JP2024520205 A5 JP 2024520205A5
- Authority
- JP
- Japan
- Prior art keywords
- modified oligonucleotide
- nucleic acid
- modified
- oligomer compound
- oligomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191905P | 2021-05-21 | 2021-05-21 | |
| US63/191,905 | 2021-05-21 | ||
| PCT/US2022/030335 WO2022246251A2 (en) | 2021-05-21 | 2022-05-20 | Compounds for modulating unc13a expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520205A JP2024520205A (ja) | 2024-05-22 |
| JP2024520205A5 true JP2024520205A5 (OSRAM) | 2025-05-26 |
Family
ID=84140868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571857A Pending JP2024520205A (ja) | 2021-05-21 | 2022-05-20 | Ｕｎｃ１３ａの発現を調節するための化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240301415A1 (OSRAM) |
| EP (1) | EP4341406A4 (OSRAM) |
| JP (1) | JP2024520205A (OSRAM) |
| WO (1) | WO2022246251A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| MX2024000996A (es) | 2021-07-21 | 2024-06-28 | AcuraStem Incorporated | Oligonucleótido antisentido unc13a. |
| GB202117758D0 (en) * | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| JP2025500335A (ja) * | 2021-12-21 | 2025-01-09 | エフ． ホフマン－ラ ロシュ アーゲー | Ｕｎｃ１３ａを標的とするアンチセンスオリゴヌクレオチド |
| CN120283053A (zh) * | 2022-10-05 | 2025-07-08 | 追踪神经科学公司 | Unc13a反义寡核苷酸和其用途 |
| WO2024178223A1 (en) * | 2023-02-24 | 2024-08-29 | Northwestern University | Antisense oligonucleotides for preventing unc13a misplicing |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| WO2025178854A2 (en) | 2024-02-19 | 2025-08-28 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting cideb and related methods |
| JP7836475B1 (ja) | 2024-03-05 | 2026-03-26 | 武田薬品工業株式会社 | Ｕｎｃ１３ａのスプライシングモジュレーションのための組成物および方法 |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| WO2026080323A1 (en) * | 2024-10-09 | 2026-04-16 | Quralis Corporation | Treatment of neurological diseases using modulators of unc13a gene transcripts |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1897942A1 (en) * | 1993-05-11 | 2008-03-12 | The University Of North Carolina At Chapel Hill | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
| US20060008800A1 (en) * | 2001-11-05 | 2006-01-12 | Christian Rosenmund | Unc-13 in the modulation of neurotransmission and secretion events |
| JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| US20110195848A1 (en) * | 2010-01-08 | 2011-08-11 | Roopra Avtar S | Gene expression and breast cancer |
| US10517889B2 (en) * | 2017-09-08 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Modulators of SMAD7 expression |
| GB2603454A (en) * | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
-
2022
- 2022-05-20 US US18/562,543 patent/US20240301415A1/en active Pending
- 2022-05-20 WO PCT/US2022/030335 patent/WO2022246251A2/en not_active Ceased
- 2022-05-20 EP EP22805616.4A patent/EP4341406A4/en active Pending
- 2022-05-20 JP JP2023571857A patent/JP2024520205A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024539596A5 (OSRAM) | ||
| RU2662962C2 (ru) | Связанные с пептидом морфолиновые антисмысловые олигонуклеотиды для лечения миотонической дистрофии | |
| RU2566724C2 (ru) | Композиции и способы модуляции smn2 сплайсинга у субъекта | |
| US6372427B1 (en) | Cooperative oligonucleotides | |
| JP2024504377A5 (OSRAM) | ||
| JP2023536472A5 (OSRAM) | ||
| JP2022518929A5 (OSRAM) | ||
| JP2022533358A5 (OSRAM) | ||
| JP2017533715A (ja) | 調節性ポリヌクレオチド | |
| KR20080031164A (ko) | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 | |
| HRP20020309A2 (en) | Treatment of fatigue, head injury and stroke | |
| HUE028036T2 (en) | Tricyclic DNA anti-sense oligonucleotides, compositions and methods for treating a disease | |
| JP2024523363A5 (OSRAM) | ||
| JP2023536994A5 (OSRAM) | ||
| RU2008130855A (ru) | ОПОСРЕДОВАННОЕ РНКI ИНГИБИРОВАНИЕ Rho-КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ НАРУШЕНИЙ | |
| JP2024540537A5 (OSRAM) | ||
| RS66986B1 (sr) | Antisense lečenje angelmanovog sindroma | |
| JP2024543214A5 (OSRAM) | ||
| JP2021534154A5 (OSRAM) | ||
| CN104080910A (zh) | 使用微rna195提供神经保护作用的方法 | |
| JP2022500079A5 (OSRAM) | ||
| JP2022515140A5 (OSRAM) | ||
| JP2024506351A5 (OSRAM) | ||
| JP2023530072A5 (OSRAM) | ||
| JP2023528755A5 (OSRAM) |